Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is atypical teratoid/rhabdoid tumor (atrt)?
Atypical teratoid/rhabdoid tumor, or ATRT, is a rare and aggressive brain tumor that occurs mostly in infants and children under three years old, though it can occasionally appear in older children and adults. It can develop anywhere in the brain or spine but often forms in the cerebellum and brainstem at the back of the head, or near the fluid-filled spaces of the brain. Because it grows quickly and can block the flow of cerebrospinal fluid, ATRT often causes symptoms over a short time — headaches, vomiting, sleepiness, loss of balance, or, in babies, a head that grows too fast and fussiness. A hallmark of ATRT is the loss of a tumor-suppressor gene (most often SMARCB1, sometimes SMARCA4), and confirming this change helps doctors make the diagnosis with certainty. ATRT can spread through the cerebrospinal fluid to other parts of the brain and spine, so treatment must consider the whole nervous system, not just the original tumor. Historically ATRT was very difficult to treat, but modern intensive, multi-part treatment programs have meaningfully improved outcomes, especially for older children whose brains can tolerate radiation. Because nearly all patients are very young, the goal is to treat this aggressive tumor swiftly and effectively while doing everything possible to protect a developing brain. Because the gene change can sometimes be inherited, genetic counseling is an important part of care.
The main types
Doctors group atypical teratoid/rhabdoid tumor (atrt) by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| ATRT of the brain | The most common location; can form in the cerebellum, brainstem, or near the brain's fluid spaces, often causing rapid symptoms from pressure buildup. |
| ATRT of the spine | Less common; forms in the spinal cord and may cause weakness, pain, or changes in bladder and bowel function. |
| Molecular subgroups (ATRT-TYR, ATRT-SHH, ATRT-MYC) | Research has identified three biological subtypes that differ in age, location, and behavior; doctors increasingly use them to refine treatment and clinical-trial options. |
Staging, in plain terms
ATRT is not staged with the TNM number system used for many adult cancers. Instead, doctors assess a few key factors that determine how treatment is planned. The first is whether the tumor has spread through the cerebrospinal fluid, which is checked with an MRI of the entire brain and spine and, when possible, a sample of the spinal fluid. The second is how much of the tumor the surgeon was able to remove. The third — and one of the most important — is the child's age, because radiation can seriously affect a very young, developing brain, so plans for infants differ from those for older children. Doctors also confirm the diagnosis by testing the tumor for loss of the SMARCB1 (or, less often, SMARCA4) gene, and increasingly identify the molecular subgroup, which can refine the outlook and treatment. Because ATRT grows quickly, evaluation and treatment are started urgently. The combination of these factors — spread, extent of surgery, age, and biology — sorts each child into a treatment intensity rather than a numbered stage.
| Risk grouping by age, spread through the spinal fluid, and surgery — not TNM | What it generally means |
|---|---|
| Localized, no spread | Tumor confined to where it started with no spread through the spinal fluid; treated with surgery to remove as much as possible, intensive chemotherapy, and radiation in children old enough to receive it safely. |
| Disseminated (spread through the spinal fluid) | Tumor cells have seeded the brain or spine; treated most intensively, often including chemotherapy and radiation directed to the affected areas or the whole brain and spine in older children. |
| Infant / very young child | In babies and toddlers, treatment leans heavily on surgery and intensive chemotherapy — sometimes high-dose chemotherapy with stem-cell rescue — to delay or limit radiation and protect the developing brain, with focused radiation used selectively. |
The standard of care
Atypical Teratoid/Rhabdoid Tumor (ATRT) is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery
An operation removes as much tumor as can be done safely, confirms the diagnosis, and relieves pressure on the brain. Removing more tumor is linked to better outcomes when it can be done safely.
Intensive multi-drug chemotherapy
ATRT is treated with strong combination chemotherapy, sometimes including medicine delivered into the spinal fluid and, in young children, high-dose chemotherapy with stem-cell rescue to allow higher doses while sparing radiation.
Radiation therapy
An important part of treatment for children old enough to receive it safely; it targets the tumor area or, if the cancer has spread, a wider field. In the youngest children it is delayed or limited to protect the brain.
Coordinated, urgent care at a specialized center
Because ATRT is rare and aggressive, the best outcomes come from prompt, coordinated treatment by a pediatric neuro-oncology team, often within a clinical trial.
Genetic counseling and survivorship
Because the gene change can be inherited, families are offered genetic counseling; long-term follow-up supports thinking, growth, hormones, hearing, and emotional health.
How radiation treatment works
Radiation therapy uses precisely aimed high-energy beams to damage the DNA inside tumor cells so they can no longer grow and divide. ATRT is sensitive to radiation, and for children old enough to receive it safely, radiation is an important part of curative treatment — studies show it improves survival. When the tumor is localized, radiation is focused tightly on the area where the tumor was; when it has spread through the cerebrospinal fluid, the whole brain and spine may be treated at a lower dose with a focused boost. The central challenge is that most children with ATRT are infants and toddlers whose brains are still developing and are highly vulnerable to radiation's long-term effects on thinking, growth, and hormones. To balance cure against these risks, teams individualize the approach: older children typically receive radiation as part of treatment, while the youngest children may have radiation delayed, reduced, or focused only on the tumor area, with intensive chemotherapy — sometimes high-dose chemotherapy with stem-cell rescue — used to control the disease in the meantime. Modern planning with intensity-modulated radiation and, where available, proton therapy allows the dose to be delivered effectively while sparing as much healthy tissue as possible. Because ATRT grows quickly, treatment is started urgently, and the radiation oncologist designs each plan to control this aggressive tumor while protecting the child's long-term development as much as possible.
The main ways radiation is delivered for atypical teratoid/rhabdoid tumor (atrt):
Focal (tumor-bed) radiation
For localized ATRT, radiation is shaped tightly around the area where the tumor was, delivering an effective dose while sparing surrounding healthy brain — the preferred approach when the disease has not spread.
Craniospinal irradiation when the tumor has spread
If cells have seeded the cerebrospinal fluid, the entire brain and spine are treated at a lower dose with a focused boost, used in children old enough to tolerate it.
Proton therapy
Proton beams stop at a set depth, so they can treat the tumor while sparing nearby healthy brain and, when treating the spine, the organs in front of it — especially valuable for protecting a young child's development.
High-dose chemotherapy with stem-cell rescue to spare radiation
In infants too young for brain radiation, very intensive chemotherapy supported by the child's own stem cells is used to control the tumor while delaying or avoiding radiation to the developing brain.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Radiation therapy improves survival in ATRT: Recent analyses confirm that adding radiation therapy increases overall survival across patients with ATRT, supporting its role in children old enough to receive it safely after surgery and chemotherapy.[1]
ATRT outcomes analyses (2025)
Intensive chemotherapy programs improve outcomes: Treatment protocols combining aggressive surgery, multi-drug chemotherapy (sometimes with high-dose chemotherapy and stem-cell rescue), and focal radiation have improved survival compared with older approaches.[2]
Pediatric ATRT cooperative protocols
Molecular subgroups refine treatment: Research identifying ATRT's biological subgroups (TYR, SHH, MYC) is helping doctors understand differences in age, location, and behavior and is guiding new clinical trials and targeted approaches.[3]
ATRT molecular classification studies
Common questions
Why does treatment start so quickly? ATRT grows fast and can spread through the spinal fluid, so doctors begin evaluation and treatment urgently. Prompt, coordinated care by a pediatric neuro-oncology team — often within a clinical trial — gives the best chance of controlling the tumor.
Can my baby avoid radiation? In very young children, doctors often delay, reduce, or limit radiation to protect the developing brain, leaning on surgery and intensive chemotherapy — sometimes high-dose chemotherapy with stem-cell rescue — first. Whether and when radiation is used depends on the child's age, how the tumor responds, and whether it has spread. Proton therapy, when available, helps spare healthy tissue.
Is ATRT inherited? The gene change behind ATRT (most often in SMARCB1) can sometimes be inherited, which is why genetic counseling and testing are offered. This can explain why the tumor developed and identify family members who may benefit from monitoring.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.